Sanjana brings extensive oncology clinical development experience to K36 across early and late stage studies. Most recently, Sanjana was the lead clinical scientist at LAVA Therapeutics and successfully brought two of bispecific gamma delta T cell engagers for heme malignancies (multiple myeloma, CLL, AML) and mCRPC from Drug Candidates to the Clinic.

 

Prior to LAVA, Sanjana worked in Oncology Clinical Development at GlaxoSmithKline, leading end to end delivery of global Phase I and Phase III studies for the ICOS program as well as for Zejula®(niraparib) in solid tumors. Sanjana began her career at TG Therapeutics where she held roles of increasing responsibility, leading clinical project management for early pipeline compounds in various hematological malignancies and contributing to the successful NDA filing and approval of umbralisib for patients with Non-Hodgkin Lymphoma. 

 

Sanjana completed her undergraduate education at New York University in Public Health and Economics and holds an MS in Biotechnology from the Johns Hopkins University.